Astellas 401(k) Settlement
Astellas Pharma Inc., a prominent player in the global pharmaceutical industry, is headquartered in the United States, with significant operations across Europe and Asia. Founded in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas has established itself as a leader in innovative healthcare solutions. The company focuses on areas such as urology, oncology, and immunology, offering unique products that address unmet medical needs. With a commitment to research and development, Astellas has achieved notable milestones, including the launch of several groundbreaking therapies. The Astellas 401(k) Settlement highlights the company's dedication to its employees' financial well-being, reflecting its strong market position and reputation for corporate responsibility. As Astellas continues to advance in the pharmaceutical landscape, it remains focused on delivering value to both patients and stakeholders.
DitchCarbon Score
How does Astellas 401(k) Settlement's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Astellas 401(k) Settlement's score of 3 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Astellas 401(k) Settlement's reported carbon emissions
Astellas, headquartered in the US, currently does not have available carbon emissions data for the most recent year, nor does it provide specific reduction targets or initiatives related to its climate commitments. Without concrete figures or defined goals, it is challenging to assess the company's carbon footprint or its strategies for mitigating climate impact. However, the absence of data may indicate a need for enhanced transparency and commitment to sustainability practices within the pharmaceutical industry. As climate change becomes an increasingly pressing issue, companies like Astellas are encouraged to establish measurable targets and report on their emissions to align with global climate action efforts.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Astellas 401(k) Settlement is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
